Table 1 Antimicrobial resistance patterns of Gram-negative bacterial pathogenic strains isolated from burn patients
Antibiotics | Antimicrobial resistant isolates n = 104 (%) | |||||
|---|---|---|---|---|---|---|
Pseudomonas | Klebsiella | Acinetobacter | Proteus | Others | Total | |
β-lactamas | ||||||
Aztreonam (ATM) | 50 (48.1) | 19 (18.3) | 13 (12.5) | 10 (9.6) | 12 (11.5) | 104 (100) |
Piperacillin (PIP) | 48 (46.2) | 18 (17.3) | 13 (12.5) | 10 (9.6) | 11 (10.6) | 100 (96.2) |
Piperacillin-tazobactam (TZP) | 40 (38.5) | 14 (13.5) | 10 (9.6) | 9 (8.7) | 7 (6.7) | 80 (76.9) |
Amoxycillin-clavulanate (AMC) | 46 (44.2) | 14 (13.5) | 12 (11.5) | 7 (6.7) | 10 (9.6) | 89 (85.6) |
Cephalosporins | ||||||
Cefotaxime (CTX) | – | 19 (18.3) | – | 10 (9.6) | 12 (11.5) | 104 (100) |
Ceftazidime (CAZ) | 50 (48.1) | 19 (18.3) | 13 (12.5) | 10 (9.6) | 12 (11.5) | 104 (100) |
Cefepime (FEP) | 45 (43.3) | 18 (17.3) | 12 (11.5) | 9 (8.7) | 12 (11.5) | 96 (92.3) |
Carbapenems | ||||||
Doripenem (DOR) | 31 (29.8) | 11 (10.6) | 5 (4.8) | 4 (3.8) | 8 (7.7) | 59 (56.7) |
Imipenem (IMI) | 28 (26.9) | 12 (11.5) | 4 (3.8) | 5 (4.8) | 11 (10.6) | 60 (57.7) |
Meropenem (MEM) | 32 (30.7) | 11 (10.6) | 5 (4.8) | 4 (3.8) | 9 (8.7) | 61 (58.7) |
Aminoglycosides | ||||||
Amikacin (AMK) | 50 (48.1) | 19 (18.3) | 13 (12.5) | 10 (9.6) | 12 (11.5) | 104 (100) |
Gentamicin (GEN) | 41 (39.4) | 17 (16.4) | 13 (12.5) | 9 (8.7) | 11 (10.6) | 91 (87.5) |
Tobramycin (TOB) | 40 (38.5) | 18 (17.3) | 12 (11.5) | 8 (7.7) | 12 (11.5) | 90 (86.5) |
Quinolones | ||||||
Ciprofloxacin (CIP) | 40 (38.5) | 18 (17.3) | 11 (10.6) | 10 (9.6) | 8 (7.7) | 87 (83.7) |
Levofloxacin (LEV) | 42 (40.4) | 16 (15.4) | 13 (12.5) | 9 (8.7) | 9 (8.7) | 89 (85.6) |